Convention Abstracts

2018 Annual Convention Workshop Abstracts

Workshop planning in progress

2017 Annual Convention Workshop Abstracts and Slide Presentation Links

Friday September 15, 2017
8:30 – 11:30 AM

Vitamin K Coagulopathy Overview: Manifestations, Diagnosis and Therapy - Part I & Part II
175-1003.0 CE (note: you must attend both parts to receive credit) – Level of Instruction: Intermediate
Tatsiana Mardovina, MD, PhD
Scientific Market Development
Paul Riley, PhD, MBA
Scientific Business Development Manager
Diagnostica Stago, Inc.
Parsippany, NJ
Sponsored by Diagnostica Stago, Inc.
Abstract: This presentation will provide an overview of potential hemostasis outcomes related to Vitamin K deficiency with special focus paid to hemorrhagic disease in newborns. Clinical cases will be presented demonstrating the major clinical features of Vitamin K deficiency along with interpretation of the laboratory evidence of impaired coagulation related to Vitamin K deficiency.

New Horizons in Autoimmune Testing
175-1013.0 C E – Level of Instruction: Intermediate
Robert Boyes, BS
Scientific Director
Inova Diagnostics
San Diego, CA
Sponsored by Inova Diagnostics, Inc.
Abstract: Autoimmune diseases affect approximately one in five Americans or 20% of the population.  These diseases often disproportionately affect women with an estimated 75% or 30 million patients being women. Testing for autoimmune diseases has been an integral component of laboratory immunology for decades but now new and exciting assays and methods are making inroads into the laboratory.  This lecture will look at the impacts of automating indirect immunofluorescent testing, discuss the impact of new biomarkers such as Calprotectin found in inflammatory bowel disease, antibodies to the PS/PT complex in antiphospholipid syndrome, and lastly, examine the role of these new biomarkers in the expanding area of personalized medicine. The difficulty level of this lecture is intermediate but those with no experience in autoimmunity will still enjoy the exposure to this exciting area of diagnostics.

Friday September 15, 2017
1:30 – 4:30 PM

Hematology Essentials: A Foundation for Accurate Smear Reviews
175-2003.0 CE – Level of Instruction: Basic
Christine A. Hinz, MS, MLS (ASCP)CM
Product Manager, IT
Sysmex America, Inc.
Lincolnshire, IL
Sponsored by Sysmex America, Inc.
Abstract: Reviewing hematology slides can be challenging. A patient’s blood picture is dependent on condition and treatment and can change over time. How can you distinguish a blast from a reactive lymphocyte? How do growth factor drugs affect WBC morphology? This workshop will take the attendees beyond the textbook on a practical journey through case studies that provide a basic review of hematology cells and morphology. Attendees will also gain insight on how to train new and current hematology technologists.

More than 50 Years Later, Where Are We Now with Gluten? The Ever-Evolving Landscape of Celiac Disease and Non-Celiac Non-Wheat Allergy Gluten Sensitivity
175-2013.0 C E – Level of Instruction: Intermediate
Wen Kumfert, PhD
Senior Global Product Manager
Bio-Rad Laboratories, Inc.
Benicia, CA
Sponsored by Bio-Rad Laboratories, Inc.
Abstract: The first scientific study that established definitive association between gluten and celiac disease was published in the 1940s.  More than 50 years later, we have learned a lot about celiac disease and celiac disease diagnostics, gluten-free diet becomes fashionable, new clinical symptom (non-celiac, non-wheat allergy gluten sensitivity) has been proposed and accepted into clinical practice, where are we now?  Rather than just presenting the key facts about celiac disease, the development of celiac diagnostics, gluten and the new non-celiac non-wheat allergy gluten sensitivity, this seminar will attempt to thread the key facts through the lens of history, illustrate a path of how these key facts came about and shed some light on the ever-evolving landscape of celiac disease and non-celiac non-wheat gluten sensitivity research.

Part I: Laboratory Diagnosis of von Willebrand Disease
Part II: Case Studies in Coagulation
175-2023.0 CE (note: you must attend both parts to receive credit) – Level of Instruction: Intermediate
Larry J. Smith, PhD, SH(ASCP), HCLD/CC(ABB)
Medical and Scientific Affairs, Liaison Manager
Abbott Diagnostics Division – Hematology
Santa Clara, CA
Sponsored by Abbott Diagnostics Division – Hematology
Abstract: Von Willebrand disease (VWD) is the most common congenital bleeding abnormality in the world that affects approximately 1-2% of the general population. Clinical laboratories often provide several screening assays that measure different properties of von Willebrand factor to aid in diagnosis, but it can still be challenging. This review provides a brief review of the structure and function of the von Willebrand factor molecule, a description of the current classification scheme for VWD, a review of the assays required and preanalytical variables affecting these assays for accurate diagnosis.

Saturday, September 16, 2017
8:30 – 11:30 AM

Part I) Procalcitonin (PCT) Use in Sepsis Management and Antibiotic Treatment Decisions
Part II) Biomarkers for the Diagnosis of Alzheimer’s Disease
Part III) Women’s Health – Biomarkers in Clinical Practice and Future Approaches
175-3003.0 CE (note: you must attend all three parts to receive credit) – Level of Instruction: Basic
M. Laura Parnas, PhD, DABCC
Sr. Scientific Affairs Manager, US MSA
Roche Diagnostics Corporation
Indianapolis, IN
Sponsored by Roche Diagnostics Corporation
Abstract (Part I): With more than 258,000 lives being lost per year, sepsis ranks as the third leading cause of death in the U.S. (after heart disease and cancer). Sepsis has been named as the expensive in-patient cost in American hospitals in 2011 at over $20 billion each year. Forty percent of patients diagnosed with severe sepsis do not survive. Until a cure for sepsis is found, early detection is the surest hope for survival. In addition, up to 50% of survivors suffer from post-sepsis syndrome.
There are biomarkers that can help provide caregivers with great clinical clarity. One such marker is Procalcitonin (PCT), a protein that consists of 116 amino acids, is the peptide precursor of calcitonin, a hormone that is synthesized by the parafollicular C cells of the thyroid and involved in calcium homeostasis. Procalcitonin arises from endopeptidase-cleaved preprocalcitonin.
Abstract (Part II): The presentation will cover Alzheimer’s disease. With ever increasing disease prevalence and incidence for early onset and late onset dementia, a need exists to build knowledge on the pathology with this disease. We will discuss the use of biomarkers for diagnosis or monitoring with disease progression with focus for how new biomarkers might influence and improve clinical practice and patient care.
Abstract (Part III): The presentation will cover diseases that are specific to female patients (breast and ovarian cancer) or have a significantly higher prevalence in women (osteoporosis) or are related to pregnancy (preeclampsia). We will discuss the use of biomarkers for screening, diagnosis, therapy monitoring or recurrence testing and how new biomarkers might influence and improve clinical practice.

Hemostasis is Unique – The Cascade, the Diseases, and the Tests – All Mixed Up
175-3013.0 C E – Level of Instruction: Intermediate
James F. DeMase, BS
Senior National Technical Sales Manager
Precision BioLogics, Inc.
Dartmouth, Nova Scotia, Canada
Sponsored by Precision BioLogics, Inc.
Abstract: This session will review the basics of hemostasis in the coagulation lab and enhance the basic understanding of hemostasis and thrombosis, describing the stages of hemostasis as well as common bleeding and clotting disorders. We will define hemophilia, and review its symptoms, diagnosis, and common treatments. The methods and clinical application of mixing studies will be outlined. Case studies will be used throughout the workshop to help attendees relate their learning to real-world situations.

Saturday, September 16, 2017
1:30 – 4:30 PM

What Made Sally Sick? The Use of Multiplex Polymerase Chain Reaction (PCR) Panels as First Line Tests for Detection of Respiratory, GI and Meningitis/Encephalitis Pathogens
175-4003.0 CE – Level of Instruction: Intermediate
Alex L. Sterling, BS
Sales Manager, Laboratory Diagnostics
BioFire Diagnostics, LLC
Salt Lake City, UT
Sponsored by BioFire Diagnostics, LLC
Abstract: Multiplex PCR panel has been available since 2008. Today, numerous PCR panels for detection of several respiratory and gastrointestinal pathogens are commercially available. In the area of testing for infectious disease, these products have become a disruptive technology in their ability to integrate molecular diagnostics and microbiology. Some of these tests are labor intensive, while others provide simple workflows; all of them are more expensive than standard technique to the laboratory and patient. Many of these assay panels can detect up to 22 pathogens. More confounding to the clinician is how these pathogens can cause similar symptoms, yet lead to different manifestations of infection within the same organ system. While some laboratories and hospitals have limited the frequency at which patients can be tested, others have allowed the ordering provider to exercise clinical judgment as to whether they are appropriate for first-line diagnostic testing.

Is this Lymphocyte Normal, Reactive or Malignant?
175-4013.0 C E – Level of Instruction: Intermediate
Steven Marionneaux, MS, MT(ASCP)
Global Manager, Scientific Affairs
Abbott Hematology
Santa Clara, CA
Sponsored by Abbott Hematology
Abstract: Lymphocyte morphology can be quite challenging at times. Normal lymphocytes are easy to call but morphology may change depending on what is happening with the patient. Infection, inflammation, drug exposure or a number of leukemias/lymphomas can alter their appearance. This session will attempt to provide criteria that can be used to objectively differentiate, identify and label different types of lymphoid cells. A method of reporting abnormal lymphoid cells will be formulated based on information discussed. Several case studies will be reviewed to illustrate how lymphoid neoplasms are currently classified by the WHO.

Sunday, September 17, 2017
8:30 – 11:30 AM

Part I) Advanced Antibody Identification: Case Studies
Part II) Laboratory Investigation of Transfusion Reactions: Case Studies
175-5003.0 CE (note: you must attend both parts to receive credit) – Level of Instruction: Intermediate
Program Director, Medical Laboratory Science, ARUP Laboratories
Assistant Professor of Pathology, Medical Laboratory Science, University of Utah School of Medicine
Salt Lake City, UT
Sponsored by ARUP Laboratories
Abstract (Part I): Difficult antibody identification cases in transfusion can be more easily resolved with knowledge of blood group antigen characteristics, antibody idiosyncrasies, and established algorithms to help know which way to go. However, even with the best of these, the process can still feel a bit like falling down a rabbit hole. In this presentation, we will explore several advanced cases, and you may be a bit surprised at the end when the answer isn’t exactly what you expect.
Abstract (Part II): Many of the signs and symptoms of transfusion reactions are shared, and not all reactions are diagnosed by tests performed in the laboratory. This session includes a review of the characteristics of acute and delayed hemolytic and nonhemolytic transfusion reactions, and several case studies are presented.

Help and Hope in Alzheimer’s Science and Care
175-5013.0 C E – Level of Instruction: Basic
Alexandra Morris, MA
Certified Professional Geriatric Care Manager
Credentialed Professional Gerontologist
Alzheimer’s Association
San Jose, CA
Sponsored by CAMLT
Abstract: The lecturer will present an update on Alzheimer’s and related disorders and current approaches to treatment. Discussion on how advances in biomarkers, brain scans and genetic testing are impacting the diagnosis, treatment, and research of Alzheimer’s. The latest in drug research and what looks promising for the future will be presented.

Sunday, September 17, 2017
1:30 – 4:30 PM

Which of the Two Make the Best Soul Mate? An Infectious or Autoimmune Antibody?
175-6003.0 CE – Level of Instruction: Basic
Maria Crisostomo, MBA
Senior Product Manager, North America Sales Division
Bio-Rad Laboratories, Inc.
Benicia, CA
Sponsored by Bio-Rad Laboratories, Inc.
Abstract: This session will take participants through a memory lane walk-through of diagnostic testing in the areas of HIV, syphilis and autoimmunity. As a basic overview, participants will be able to regain an understanding of the evolution of testing in these three areas, their respective testing algorithms and how the “perfect” pairing of antigen and antibody contributes to laboratory’s decision as to which tests are appropriate for their patient population and laboratory workflow.

Part I) California’s Medical Laboratory Technician Workforce: Research and Policy Implications
Part II) How to Improve the Laboratory Experience - CLS and MLT Working Together
175-6013.0 C E (note: you must attend both parts to receive credit) – Level of Instruction: Intermediate
Susan Chapman, PhD, MPH, MSN, BSN
University of California, San Francisco – School of Nursing
San Francisco, CA
Dora W. Goto, MS, CLS, MLS(ASCP)CM
California Association for Medical Laboratory Technology
Fremont, CA
Abstract (Part I): California faces laboratory workforce shortages to meet the healthcare demands of the population. The state developed regulations for the MLT more than a decade ago. Yet growth in the utilization of MLTs has been slow in many organizations and parts of the state. This national study compares the California MLT workforce to other states. MLT supply is scarce and the scope of practice laws are more restrictive than any other state. Laboratory personnel in other states that regulate MLTs generally support MLTs practicing to their highest level of training. Several policy implications that need to be considered for future growth of the MLT role in California.
Abstract (Part II): Until December 19, 2007, only Clinical Laboratory Scientists (CLS) were recognized as testing personnel in California laboratories. A newer category of laboratory testing personnel known as Medical Laboratory Technicians (MLT) had begun to be recognized as testing personnel in California as well. In addition, regulations certifying Phlebotomists (CPT) have been in effect since 2003. Official recognition of these categories provides a “career ladder” within our laboratories and will help staff laboratories with appropriately trained personnel. Licensure of mid-level testing personnel as MLTs will positively impact the laboratory personnel workforce shortage in California, but will not solve all our staffing issues nor take the place of the CLS.

Optional User Login
Thank you to our Fun Night Sponsor

Job Board
CAMLT Loyalty Partners
Contact Us:

CAMLT Executive Office Address:
39656 Mission Blvd.
Fremont, California 94539


Telephone: 510.792.4441
Fax: 510.792.3045

Office Hours:
Mon – Fri: 8 a.m. – 4:30 p.m.
excluding holidays
Sat & Sun: Office Closed